Safety
neurotoxicities, nausea, diarrhea, toxicities, Hypoimmunoglobulinemia, CRS, vomiting, constipation, abdominalgia, Neurotoxicity, non-IgA MM
EVENTS, B-CELL APLASIA, HYPOIMMUNOGLOBULINEMIA, DISEASE PROGRESSION
Hematologic toxicities were the most common AEs (Table AEsCRS was observed in 25 (76%) of 33 patients, and no grade 3 or higher CRS was observed (Table Neurotoxicity events after anti-GPRC5D CAR T-cell infusion, including ICANS and other neurotoxicities, occurred in three (9%) of 33 patients (Table Gastrointestinal events, mainly nausea, occurred in nine (27%) patients, with seven having recurrent vomiting. Five (15%) patients experienced constipation, three (9%) diarrhea, and two (6%) abdominalgia (Table One patient (patient 14) died during follow-up. The patient achieved a PR on day 14 after CAR T-cell infusion. A decreased platelet count was observed in the patient because of disease progression before CAR T-cell therapy, and the platelet counts were below the level of 20 × 10All the 33 patients developed B-cell aplasia. B-cell aplasia was observed in 97%, 80%, and 50% of patients at 1, 2, and 3 months, respectively (Data Supplement). Hypoimmunoglobulinemia already existed in 29 (88%) patients before anti-GPRC5D CAR T-cell infusion. Serum IgA (in patients with non-IgA MM), IgM (in patients with non-IgM MM), and IgG (in patients with non-IgG MM) decreased significantly after CAR T-cell infusion compared with baseline concentrations. Recovery of serum IgM to a normal level was observed in 40% (8 of 20) of patients after 3 months, and IgG and IgA had not recovered to the normal concentration at data cutoff, except three patients.